Invokana® Injury Lawsuits
Invokana® (canagliflozin), Invokamet® (canagliflozin and metformin), and Invokamet XR® (canagliflozin and metformin hydrochloride extended-release) are prescription drugs used in the treatment of Type 2 diabetes. But patients who take these drugs may face an increased risk of severe side effects, including ketoacidosis (high levels of acid in the blood) and amputation of the leg or foot.
You may be entitled to compensation if you lost a loved one who took Invokana®, Invokamet®, or Invokamet XR®, or you suffered any of the following injuries after taking one of the drugs:
- Amputation of the leg or foot
- Kidney failure
At Ferrer, Poirot & Wansbrough, our drug injury lawyers are here to protect your rights. We’ve recovered millions of dollars* for our clients, and we have the resources and experience to help you get the compensation you need. Dial (800) 210-8503 or complete our free online form to get started now.
Invokana®, Invokamet®, and Invokamet XR® Linked to Amputations
On May 16, 2017, the U.S. Food and Drug Administration (FDA) reviewed data from two large clinical trials that indicate patients who take the Type 2 diabetes drug canagliflozin—sold as Invokana, Invokamet, and Invokamet XR—are at an increased risk of leg and foot amputations.
In response, the FDA issued a Drug Safety Communication and required that the manufacturers of the drugs include new Boxed Warnings—the most prominent drug warnings—on the labels of the medications.
The trials found that the most common amputations involved the toe and middle of the foot, but some patients required amputation below and above the knee or even multiple amputations.
Invokana® and Invokamet® Ketoacidosis Risk
Ketoacidosis is a serious medical condition normally associated with patients with Type 1 diabetes. But since March 2013, the FDA has received more than 20 reports of acidosis—including diabetic ketoacidosis (DKA), ketoacidosis, and ketosis—among Type 2 diabetics treated with SGLT2 inhibitors—a class of medications that includes Invokana and Invokamet.
In May 2015, the FDA issued a drug safety communication that warned of a potential link between taking SGLT2 inhibitors and developing ketoacidosis. FDA officials are urging health care professionals and patients to report SGLT2 side effects as they continue to investigate if prescribing information for the drugs needs to be changed.
What Are the Symptoms of Ketoacidosis?
Symptoms of ketoacidosis include:
- Difficulty breathing
- Abdominal pain
- Unusual fatigue or sleepiness
Patients who experience signs of ketoacidosis while taking Invokana, Invokamet, or other SGLT2 inhibitors should seek medical attention immediately.
What Triggers Ketoacidosis?
The FDA reports that three factors may potentially trigger ketoacidosis in patients taking SGLT2 inhibitors:
- Major illness
- Reduced food and fluid intake
- Reduced insulin dose
Our Invokana® Lawyers Want to Help
Ferrer, Poirot & Wansbrough believes in reforming the pharmaceutical industry through litigation, and we want to fight for you. There are strict deadlines for filing drug injury lawsuits, so don’t wait to get help if you or a loved one suffered complications, such as an amputation or ketoacidosis, after taking Invokana, Invokamet, or Invokamet XR. Contact our 24/7 legal team anytime–just dial (800) 210-8503 or complete a free initial consultation form.
Invokana® and Invokamet® are registered trademarks of Janssen Pharmaceuticals, Inc.
This law firm is not associated with, sponsored by, or affiliated with Janssen Pharmaceticals, Inc., or the U.S. Food and Drug Administration.
*Zyprexa, Seroquel and Avandia gross settlements; attorney fees and expenses deducted.